Actavis infringes Orexo’s long term Zubsolv® US patent ´330
Uppsala, Sweden – January 11, 2019 – Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the United States District Court for the District of Delaware has issued a final, non-appealable judgement that Actavis’s generic Zubsolv products infringe Orexo’s US patent No. 8,940,330. The judgement will prevent Actavis from commercializing their infringing generic Zubsolv products in the US until after September 18, 2032. The infringement judgement now issued by the District Court follows from the decision from the US